Prevalence, impact on morbidity, and disease burden

The Premenstrual Syndromes: PMS and PMDD

Volumn , Issue , 2007, Pages 37-48

  Pearlstein, Teri ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057698072     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Halbreich U, Endicott J, Schacht S et al. The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form. Acta Psychiatr Scand 1982; 65:46-65.
2. Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated with the menstrual cycle in a communitybased sample in the Midwestern United States. Psychiatry Res 2005; 134:27-36.
3. Pearlstein T, Yonkers KA, Fayyad R et al. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord 2005; 85:275-82.
4. Sternfeld B, Swindle R, Chawla A et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002; 99:1014-24.
5. Premenstrual dysphoric disorder. In: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Press; 2000:771-4.
6. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9:41-9.
7. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996; 65:97-106.
8. Steiner M, Streiner DL, Steinberg S et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53:269-73.
9. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968; 30:853-67.
10. Gehlert S, Hartlage S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 1997; 18:36-44.
11. Hurt SW, Schnurr PP, Severino SK et al. Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints. Am J Psychiatry 1992; 149:525-30.
12. Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-6.
13. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11 (Suppl 3):89-95.
14. Ware JE, Kosinski M, Bayliss MS et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33:AS264-79.
15. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33:1111-15.
16. Bloch M, Schmidt PJ, Rubinow DR. Premenstrual syndrome: evidence for symptom stability across cycles. Am J Psychiatry 1997; 154:1741-6.
17. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147:1634-6.
18. Cohen LS, Soares CN, Otto MW et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70:125-32.
19. Wittchen HU, Becker E, Lieb R et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32:119-32.
20. Perkonigg A, Yonkers KA, Pfister H et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65:1314-22.
21. Wittchen HU, Perkonigg A, Pfister H. Trauma and PTSD - an overlooked pathogenic pathway for premenstrual dysphoric disorder? Arch Womens Ment Health 2003; 6:293-7.
22. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6:203-9.
23. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med 1999; 8:1043-52.
24. Robinson RL, Swindle RW. Premenstrual symptom severity:impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med 2000; 9:757-68.
25. Vichnin M, Freeman EW, Lin H et al. Premenstrual syndrome (PMS) in adolescents: severity and impairment. J Pediatr Adolesc Gynecol 2006; 19:397-402.
26. Derman O, Kanbur NO, Tokur TE et al. Premenstrual syndrome and associated symptoms in adolescent girls. Eur J Obstet Gynecol Reprod Biol 2004; 116:201-6.
27. Halbreich U, Borenstein J, Pearlstein T et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28:1-23.
28. Logue CM, Moos RH. Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 1986; 48:388-414.
29. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104:110-16.
30. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243:23-32.
31. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8:122-8.
32. Andersch B, Wendestam C, Hahn L et al. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 1986; 5:39-49.
33. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988; 33:340-6.
34. Ramcharan S, Love EJ, Fick GH et al. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992; 45:377-92.
35. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982; 72:1257-64.
36. Tabassum S, Afridi B, Aman Z et al. Premenstrual syndrome: frequency and severity in young college girls. J Pak Med Assoc 2005; 55:546-9.
37. Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder - a study from India. Int J Fertil Womens Med 2000; 45:342-4.
38. Hsiao MC, Liu CY, Chen KC et al. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr Scand 2002; 106:150-5.
39. Sveindottir H. Prospective assessment of menstrual and premenstrual experiences of Icelandic women. Health Care Women Int 1998; 19:71-82.
40. van den Akker OB, Eves FF, Service S et al. Menstrual cycle symptom reporting in three British ethnic groups. Soc Sci Med 1995; 40:1417-23.
41. Hasin M, Dennerstein L, Gotts G. Menstrual cycle related complaints:a cross-cultural study. J Psychosom Obstet Gynaecol 1988; 9:35-42.
42. Freeman EW. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics 2005; 23:433-44.
43. Rapaport MH, Clary C, Fayyad R et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005; 162:1171-8.
44. Barnard K, Frayne SM, Skinner KM et al. Health status among women with menstrual symptoms. J Womens Health 2003; 12:911-19.
45. Winter EJ, Ashton DJ, Moore DL. Dispelling myths: a study of PMS and relationship satisfaction. Nurse Pract 1991; 16:34, 7-40,45.
46. Hardie EA. PMS in the workplace: dispelling the myth of cyclic dysfunction. J Occup Organiz Psychol 1997; 70:97-102.
47. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Womens Health 1998; 7:893-907.
48. Singh BB, Berman BM, Simpson RL et al. Incidence of premenstrual syndrome and remedy usage: a national probability sample study. Altern Ther Health Med 1998; 4:75-9.
49. Ryser R, Feinauer LL. Premenstrual syndrome and the marital relationship. Am J Fam Ther 1992; 20:179-90.
50. Hallman J, Georgiev N. The premenstrual syndrome and absence from work due to illness. J Psychosom Obstet Gynaecol 1987; 6:111-19.
51. Corney RH, Stanton R. A survey of 658 women who report symptoms of premenstrual syndrome. J Psychosom Res 1991; 35:471-82.
52. Campbell EM, Peterkin D, O’Grady K et al. Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med 1997; 42:637-46.
53. Kuan AJ, Carter DM, Ott FJ. Distress levels in patients with premenstrual dysphoric disorder. Can J Psychiatry 2002; 47:888-9.
54. Gallant SJ, Popiel DA, Hoffman DM et al. Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder. Part II. What makes a “real” difference? Psychosom Med 1992; 54:167-81.
55. Kuczmierczyk AR, Labrum AH, Johnson CC. Perception of family and work environments in women with premenstrual syndrome. J Psychosom Res 1992; 36:787-95.
56. Frank B, Dixon DN, Grosz HJ. Conjoint monitoring of symptoms of premenstrual syndrome: impact on marital satisfaction. J Couns Psychol 1993; 40:109-14.
57. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder:is there an economic burden of illness? Med Care 2002; 40:1101-12.
58. Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 1997; 33:13-16.
59. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48:515-24.
60. Dean BB, Borenstein JE. A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. J Occup Environ Med 2004; 46:649-56.
61. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332:1529-34.
62. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome:the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62:177-90.
63. Steiner M, Brown E, Trzepacz P et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6:71-7.
64. Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100:435-44.
65. Miner C, Brown E, McCray S et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24:417-33.
66. Su TP, Schmidt PJ, Danaceau MA et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16:346-56.
67. Yonkers KA, Halbreich U, Freeman E et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278:983-8.
68. Halbreich U, Bergeron R, Yonkers KA et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100:1219-29.
69. Pearlstein TB, Halbreich U, Batzar ED et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61:101-9.
70. Freeman EW, Rickels K, Sondheimer SJ et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004; 161:343-51.
71. Freeman EW, Rickels K, Sondheimer SJ et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56:932-9.
72. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004; 66:707-13.
73. Pearlstein TB, Bellew KM, Endicott J et al. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005; 7:53-60.
74. Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005; 193:352-60.
75. Freeman EW, Sondheimer SJ, Sammel MD et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005; 66:769-73.
76. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new lowdose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492-501.
77. Pearlstein TB, Bachmann GA, Zacur HA et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414-21.
78. Apter D, Borsos A, Baumgartner W et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8:37-51.
79. Borenstein J, Yu HT, Wade S et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003; 48:79-85.
80. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry 1996; 57:56-60.
81. Blake F, Salkovskis P, Gath D et al. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998; 45:307-18.
82. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990; 47:270-5.
83. Borenstein J, Chiou CF, Dean B et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47:26-33.